In a busy week, Regulus Therapeutics signed a microRNA biomarker pact with Biogen Idec ($BIIB), announced an miRNA therapeutics deal with AstraZeneca ($AZN) and filed an IPO of $57.5 million.
Paris-based biotech Exonhit Therapeutics has established a research pact with Pfizer to discover Alzheimer's disease biomarkers via a pilot study. The study will use Exonhit's Genome-Wide SpliceArray
BGI will take all that sequencing power it possesses as the world's largest genomics center--the same power that helped crack the German E. coli case --and put it together with Merck ($MRK), one of
BioArray News reports on Dortmund, Germany-based Protagen's continuing mission to partner with other companies on biomarker discovery. The latest is a deal with Biogen Idec to discover biomarkers for
Caliper Life Sciences and HistoRx are pooling their resources to produce a new way of imaging and analyzing tissue to measure proteins based on immuno-fluorescence. According to a release, the
Nuclea Biotechnologies, based in Pittsfield, MA, is partnering with the Boston Medical Center to research and develop biomarkers for patients with breast and prostate cancers. Under the partnership,